Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 692,569
  • Shares Outstanding, K 13,097
  • Annual Sales, $ 187,800 K
  • Annual Income, $ 11,990 K
  • 60-Month Beta 0.82
  • Price/Sales 3.76
  • Price/Cash Flow 39.04
  • Price/Book 3.46
Trade EGRX with:

Options Overview

Details
  • Implied Volatility 57.93%
  • Historical Volatility 43.58%
  • IV Percentile 16%
  • IV Rank 29.67%
  • IV High 88.02% on 10/26/20
  • IV Low 45.24% on 05/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.18
  • Number of Estimates 1
  • High Estimate 0.18
  • Low Estimate 0.18
  • Prior Year 0.51
  • Growth Rate Est. (year over year) -64.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.02 +12.45%
on 08/26/21
55.50 -4.72%
on 08/31/21
+4.11 (+8.43%)
since 08/13/21
3-Month
40.76 +29.74%
on 06/23/21
55.50 -4.72%
on 08/31/21
+11.39 (+27.45%)
since 06/15/21
52-Week
36.48 +44.96%
on 06/02/21
55.50 -4.72%
on 08/31/21
+14.20 (+36.71%)
since 09/15/20

Most Recent Stories

More News
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature...

EGRX : 52.88 (-1.91%)
Company News for Sep 1, 2021

Companies in the news are: NTES, SONN, EGRX, ZEV

NTES : 84.96 (+0.52%)
EGRX : 52.88 (-1.91%)
SONN : 0.6294 (+11.42%)
ZEV : 9.15 (+1.78%)
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

/PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on District Court for the District of non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent...

EGRX : 52.88 (-1.91%)
ENDP : 2.83 (+6.39%)
Eagle Pharmaceuticals Wins Vasopressin Patent Trial

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe...

EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled "Formulations...

MYL : 15.86 (+1.96%)
EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

-- Results of first-in-human(1 )clinical trial published in The Lancet Infectious Diseases, where accompanying comments characterized CAL02 as "One step closer to precision medicine for infectious diseases,"...

EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals: Q2 Earnings Snapshot

WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Monday reported second-quarter net income of $3.6 million, after reporting a loss in the same period a year earlier.

EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals Reports Second Quarter 2021 Results

--Announced licensing agreement for U.S. commercial rights to Landiolol, a beta-1 adrenergic blocker and a leading hospital emergency use product in Europe and Japan

EGRX : 52.88 (-1.91%)
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

-- Anticipates filing new drug application ("NDA") in Q1 2022, with expected ten-month review, based on well-defined feedback from U.S. Food and Drug Administration provided during AOP Orphan's Type C...

EGRX : 52.88 (-1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 55.98
2nd Resistance Point 55.22
1st Resistance Point 54.05
Last Price 52.88
1st Support Level 52.12
2nd Support Level 51.36
3rd Support Level 50.19

See More

52-Week High 55.50
Last Price 52.88
Fibonacci 61.8% 48.23
Fibonacci 50% 45.99
Fibonacci 38.2% 43.75
52-Week Low 36.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar